40
Participants
Start Date
July 31, 2007
Primary Completion Date
December 31, 2010
Study Completion Date
December 31, 2024
olanzapine and melatonin
In treatment phase I, all subjects will receive olanzapine, 10-25 mg/day. In treatment phase II, all subjects will receive olanzapine (10-25 mg/day) plus melatonin. Subjects will be randomized at a ratio of 1:1 to receive melatonin, 0.3 mg/day or 3.0 mg/day. Group IIA will receive 0.3mg day melatonin. Group IIB will receive 3.0 mg/day melatonin.
VA Puget Sound Health Care System, Tacoma
Eli Lilly and Company
INDUSTRY
Seattle Institute for Biomedical and Clinical Research
OTHER